Industry / Czech Republic
Generic Drugmakers Falter In H108
July 2008 | Industry NewsThe first half of 2008 has brought mixed results for pharmaceutical companies operating in Romania. Often considered as a high potential market for investment, it appears that the country's ongoing health reforms may be harming foreign generic makers, particularly those without strong branding for their
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
